TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00183469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine
Description: If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex (DIV) ER
Description: If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
Study: NCT00507182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: 1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
Study: NCT00529568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: double-blind matched placebo control daily oral administration
Study: NCT02444182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
Study: NCT01462474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m2, D1, D22, and D43(q3w)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation（IMRT）
Description: IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
Study: NCT00566631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
Study: NCT03605771

Intervention type: OTHER
Intervention: Daily Clinical Practice
Description: The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
Study: NCT00766506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fentanyl IONSYS
Description: Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine IV PCA
Description: Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
Study: NCT02073188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBGStar

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Glucometer
Study: NCT01431235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for treating ADHD symptoms
Description: 5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
Study: NCT00821041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
Study: NCT00479401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexol Extended Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexol Immediate Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01011907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
Study: NCT02023320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose of blueberry dry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose of blueberry dry powder
Study: NCT00611741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide, Na supplements
Description: furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
Study: NCT01771419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Loop-tip wire (Cook Medical) for the cannulation of the CBD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulotome CT-25mm Cook Medical
Study: NCT03764553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Iv liposomal irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV Leucovorin
Study: NCT05966870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsweetened flavored sparkling water
Description: Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
Study: NCT01683552

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: 125 mg on day 1; 80 mg on day 3; 80 mg on day 5

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: 125 mg on day 1; 80 mg on day 3; 80 mg on day 5
Study: NCT04198779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APPLI
Description: The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
Study: NCT03141502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin stretching device (SSD)
Description: By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin grafting
Description: the standard technique of skin grafting after wound preparation.
Study: NCT00738842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: Oral tablets taken bid for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD6140
Description: Oral tablets taken bid for 5 days
Study: NCT03219944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: : Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sub epithelial connective tissue graft
Description: sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
Study: NCT02669329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting device with vacuum applicator.
Description: The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
Study: NCT03818373

Intervention type: PROCEDURE
Group type: OTHER
Intervention: polysomnography
Description: Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
Study: NCT05549102

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioural Therapy
Description: In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.

Intervention type: OTHER
Intervention: Waiting List
Description: In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
Study: NCT02038114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructed to read patient education pamphlets
Description: The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
Study: NCT03322449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Diet
Description: during one week participants will receive food products enriched in animal products and with high content of fat and protein
Study: NCT01683552

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),

Intervention type: DRUG
Group type: OTHER
Intervention: Fexofenadine
Description: In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
Study: NCT03020836

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to primary care physician for hypertension control
Description: Referral to primary care physician for hypertension control

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to smoking quit line
Description: Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
Study: NCT01303588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong
Description: 12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
Study: NCT02576054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Study: NCT00751998

Intervention type: DEVICE
Intervention: SpyGlass
Description: The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
Study: NCT03292965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
Study: NCT01543815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Therapy based on Web Mobile Technology
Description: The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standardized Care Management
Description: CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
Study: NCT04315389

Intervention type: DEVICE
Intervention: (1) Mobile Assistant Balance Robot
Description: MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.

Intervention type: DEVICE
Intervention: (2) Transfer Assistive Cobot
Description: TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
Study: NCT03196648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival health formulation in an accelerating device
Description: The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival health formulation on a toothbrush
Description: The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTC fluoride toothpaste
Description: OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC fluoride toothpaste
Description: OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTC fluoride toothpaste
Description: OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
Study: NCT02808962

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cooled RFA of sacral lateral branches
Description: A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
Study: NCT03322449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant Diet
Description: during one week participants will receive plant products enriched in fiber and complex carbohydrates
Study: NCT04097119

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary supplementation
Description: Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
Study: NCT04427280

Intervention type: DIAGNOSTIC_TEST
Intervention: Throat/nose swabs
Description: Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva collection
Description: Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5mL) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Approximately 30mL of blood will be taken at each study visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Approximately 30mL of blood will be taken at each study visit.
Study: NCT03300388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 (DHA-rich dietary supplement)
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 (DHA-rich dietary supplement)
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (olive oil)
Description: Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
Study: NCT06541418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretic Model Based Behavior Change Program
Description: The Behavior Change Program was implemented in 7 sessions of 50 minutes, once a week. Each session in the Behavior Change Program; The warm-up exercise consisted of giving general information about the purpose and the main theme of the session, discussion and feedback on the subject, and the planning of the next week, and a closing process. The Transtheoretic Model Based Behavior Change Program was prepared by the researcher with reference to the behavior change programs in the literature and the elements of the Transtheoretic model.
Study: NCT01630265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard written discharge instructions
Description: Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Discharge Instructions
Description: Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
Study: NCT02055183

Intervention type: DRUG
Intervention: BAT
Description: Noninterventional, retrospective, observational phase 4 patient Registry